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Purpose/Objective: Ion beams due to superior dose profile 
over photons and electrons may provide higher dose-
conformity and healthy tissue sparing. But due to high costs 
and huge size ion beam therapy is limited to a few centers 
only. A novel ion acceleration process via ultra-intense laser-
matter interaction, promises size and cost reduction. 
However, laser-driven beams are characterized by intense 
particle bunches with peak dose rates exceeding 
conventional values by several orders of magnitude, low 
repetition rate, broad energy spread and large divergence, 
thus are diverse from conventional beams. This requires new 
solutions for developing Laser-based Ion Beam Therapy (LIBT) 
for clinical application. The presented work is a result of an 
ongoing joint translational research project of several 
institutions aiming to establish LIBT with protons and shows 
the status in five main challenges. 
Materials and Methods: I) Laser-based technology has been 
established, with protons (upto 20 MeV) via 150 TW laser 
system, for systematic radiobiological studies with human 
cell-lines and small animals with fixed beamline. 
II) For translation towards patient irradiation, increase of 
proton energy from 20 to 230 MeV by increasing the laser 
power from 150 TW to ~1 PW is required and in progress. 
III) Furthermore, a compact ion beam gantry system is 
designed based on pulsed magnets (PM), with integrated 
laser-particle acceleration chamber, novel beam capturing 
and energy selection system. A new pulsed scanning system 
for wide beams with broad energies is designed for 
irradiations with clinical accuracy. 
IV) The light-weight iron-less high-field PMs are being 
developed for gantry realization. These are non-trivial and 
extremely challenging to design.  
V) A new 3D TPS has been developed for new dose delivery 
and treatment planning strategies for LIBT.  
Results: No overall difference in the radiobiological 
effectiveness between laser-driven and conventional beams 
was detected to date. Therefore, a comparison of dose plans 
by treatment planning system is possible to evaluate the 
features of LIBT. The evaluation of treatment plans shows 
laser driven broad energetic beams are feasible for clinical 
application.  
Our double-achromatic 360° isocentric pulsed gantry design 
is ~2.5x smaller than conventional gantries (see fig.) and is 
capable of disperssionless scanning of high acceptance beams 
through 20x20 cm2 field size.  
For the realization, PMs have been designed and developed. 
A pulsed solenoid, for particle capturing and focusing, has 
been successfully tested at laser-driven beams. A novel 10 T 
compact pulsed 45° sector magnet has been developed and 
tested. Also, a pulsed high acceptance quadrupole with 250 
T/m gradient is being developed. 
 
 
 
Conclusions: LIBT is a promising compact alternative and 
could change IBT, yet requires substantial development 
towards clinical application.  
Supported by German BMBF, no. 03Z1N511 & DFG cluster of 
excellence MAP. 
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Purpose/Objective: Radiation treatment planning with a 
commercial TPS is a trial and error process that often leads 
to sub-optimal organ sparing. We developed a method to 
predict feasible target and organ at risk (OAR) dose levels 
prior to the start of the treatment planning process. These 
predictions can be used (i) to guide the treatment planner to 
achieve optimal OAR sparing or target dose escalation; (ii) for 
quality assurance of the treatment planning process; (iii) to 
identify patients that may benefit from adaptive RT; (iv) to 
S128                                                                                                                                         3rd ESTRO Forum 2015 
 
facilitate shared decision making e.g. based on expected 
side-effects. The method was investigated for a large cohort 
of non-small cell lung cancer (NSCLC) patients treated with a 
dose-escalation protocol. 
Materials and Methods: All NSCLC patients treated in 2013 
with concurrent chemo-radiotherapy according to an 
institutional isotoxic dose-escalation protocol were included. 
The prescribed dose to the PTV was escalated up to 69 Gy 
keeping within the OAR dose constraints, e.g., a mean lung 
dose (MLD) of 20 Gy or a maximum spinal cord dose of 54 Gy. 
Patients were treated using volumetric modulated arc 
therapy. For 50 randomly selected patients (training cohort) 
the dose in the OAR voxels was calculated as function of the 
distance to the planning target volume (PTV). Next, for the 
lungs and spinal cord, the average dose-distance relation of 
the patients in the training cohort was calculated. For the 
remaining patients (validation cohort) these average-dose 
distance relations were used to predict dose-volume 
histograms (DVHs) based on the shape and orientation of the 
OARs and PTV. By scaling the DVHs of the OARs up to the 
dose constraints, the maximum achievable mean PTV dose 
could be predicted as well. The predicted and achieved DVHs 
were compared. 
Results: Of the 92 patients, 88 were retrieved and analysed 
and four excluded due to modified OAR constraints. The 
training and validation group consisted of 50 and 38 patients, 
respectively. The difference between the predicted and 
achieved MLD in the validation cohort was small and 
statistically insignificant (0.2 ± 1.8 Gy; p = 0.45) . The 
achieved mean PTV dose varied from 52 to 73 Gy and could 
be predicted correctly with an accuracy of 2 Gy for 87% of 
the patients. The spinal cord was dose limiting in only one 
patient and this was correctly predicted. Figure 1 presents 
the average dose-distance relations of all voxels in the lungs 
for the training group. The small variation in dose, especially 
in the region close to the PTV, emphasizes the usefulness of 
geometry-based plan comparison. 
 
Conclusions: We have shown that the MLD and the prescribed 
PTV dose could be accurately predicted for NSCLC patients 
treated with arc therapy prior to the treatment planning 
process. This method is suitable for other treatment sites as 
well can be used to guide the treatment planner to achieve 
optimal OAR sparing or tumour dose escalation. In addition, 
new personalized strategies of dose escalation and shared 
decision making are envisioned.  
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Purpose/Objective: There is a huge difference in 
radiosensitivity of lungs between patients, which may further 
individualise therapy. Moreover, if regional radiosensitivities 
could be quantified, radiation dose redistribution will 
become feasible. The present study aims to identify and 
quantify individual and regional radiosensitivity based on a 
single pre-treatment CT scan (CT0). 
Materials and Methods: 110 non-small cell lung cancer 
patients were studied: 40 treated with stereotactic ablative 
radiotherapy (SABR) for stage I (3x18 Gy, 4x12 Gy or 8x7.5 
Gy), 40 treated conventionally (CONV1) for stage III (24x2.75 
Gy sequential or 33x2 Gy concurrent with chemo), and 30 
treated conventionally (CONV2) from an external validation 
set (30x1.5 Gy followed by 12x2 Gy). 
A 3 month follow-up scan (CT3M) was non-rigidly registered to 
CT0. Lung volumes were segmented per dose bin of 5 Gy, and 
their median difference in Hounsfield Units was calculated 
(ΔHU=HU3M-HU0). Linear and sigmoidal fits (parameters 
ΔHUmax (saturation of ΔHU) and D50 (dose corresponding to 
50% of ΔHUmax)) were made for ΔHU versus local dose, both 
for physical dose (D) and equivalent dose (EQD2: 
alpha/beta=4 Gy, proliferation rate=0.44 Gy/day).  
Multivariate regression was performed for D50 and ΔHUmax 
using covariates PTV volume, tumour location, heart Dmax, 
median HU0 in the V40 region, overall treatment time (OTT), 
and timepoint of CT3M. 
This prognostic model defining sensitive individuals was 
tested to define sensitive regions within one lung. Therefore, 
two lung subvolumes with the highest possible difference in 
density were manually generated on CT0 (Figure 1). 
Results: Sigmoidal fits using EQD2 outperformed the other 
scenarios for SABR and CONV1: median sum of squares 
(CONV1 between brackets) of 170.0 (517.2), 187.7 (477.5), 
109.5 (326.6) and 100.7 (320.4) for linear (D), linear (EQD2), 
sigmoidal (D) and sigmoidal (EQD2) fits respectively. This was 
validated in CONV2: 685.1 and 527.5 for linear and sigmoidal 
EQD2 fits respectively. The distributions (in percent of 
patients) of D50 and ΔHUmax reflect a large sensitivity 
variation (Table 1). 
No prognostic factors were found for D50, while a higher 
baseline lung density (p=0.004) and left lung (p=0.05) were 
prognostic for higher ΔHUmax.  
The expected ΔHU were seen in selected subvolumes (Figure 
1). Redistribution IMRT plans avoiding the high density 
volumes were generated. Approximately 50% of patient lungs 
present a composition suitable for redistribution planning. 
 
 
 
 
 
 
